NASDAQ · Healthcare
Biogen Inc. (BIIB) stock research
Biogen Inc. (BIIB) is listed on NASDAQ. Biogen Inc. reported revenue of $9.9B in the fiscal year that ended on 2025-12-31. Revenue rose 2.2% from the year before. Biogen Inc.’s net income for that year was $1.3B. The SEC classifies it under Biological Products, (No Diagnostic Substances). It is incorporated in Delaware. Its most recent SEC filing is Form 10-Q (quarterly report), filed on 2026-07-29.
Open BIIB in Willow. Filings, fundamentals, recent news — sourced stock research, no recommendation.
Annual financials
As tagged by Biogen Inc. in its annual reports on SEC EDGAR. The latest year is from Form 10-K, filed on 2026-02-06.
| Fiscal year ended | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2025-12-31 | $9.9B | $1.3B | $8.79 |
| 2024-12-31 | $9.7B | $1.6B | $11.18 |
| 2023-12-31 | $9.8B | $1.2B | $7.97 |
Recent SEC filings
Filed with the SEC under CIK 0000875045. Every row is read from the filing itself on EDGAR, not from a summary of it.
- 10-Q (quarterly report) filed 2026-07-29 · period ending 2026-06-30
- 8-K (current report) filed 2026-07-29 · period ending 2026-07-29
- 8-K (current report) filed 2026-07-01 · period ending 2026-07-01
- 8-K (current report) filed 2026-06-10 · period ending 2026-06-09
- 8-K (current report) filed 2026-05-14 · period ending 2026-05-14
- 10-Q (quarterly report) filed 2026-04-29 · period ending 2026-03-31
Filing history read from SEC EDGAR on 2026-10-19.
What a Willow brief on BIIB checks
- Recent filings and company disclosures.
- TTM fundamentals and valuation context.
- Recent news and market context separated from primary filings.
- Bull case, bear case, key risks, and watch-next items in a non-directional register.
Questions about BIIB
- What was Biogen Inc.’s revenue in the fiscal year ended 2025-12-31?
- $9.9B for the fiscal year that ended on 2025-12-31, as reported in Form 10-K filed on 2026-02-06.
- Was Biogen Inc. profitable in the fiscal year ended 2025-12-31?
- Yes. It reported net income of $1.3B for the fiscal year that ended on 2025-12-31.
- What were Biogen Inc.’s diluted earnings per share in the fiscal year ended 2025-12-31?
- $8.79 per diluted share for the fiscal year that ended on 2025-12-31.
- What is Biogen Inc.’s most recent SEC filing?
- Form 10-Q (quarterly report), filed on 2026-07-29. brief.finance reads it directly from SEC EDGAR.
- When does Biogen Inc.’s fiscal year end?
- Its SEC registration lists the year end as 31 December. The annual figures on this page cover the fiscal year that ended on 2025-12-31.
- What is Biogen Inc.’s SEC CIK number?
- 0000875045. EDGAR uses this Central Index Key to identify every filing the company submits.
- What does a Willow brief on BIIB include?
- Recent SEC filings, fundamentals and valuation context, price history, and both a bull case and a bear case. Every figure links to the source it came from.
- Does brief.finance say whether to buy or sell BIIB?
- No. brief.finance publishes educational research and does not recommend buying, selling, or holding any security.
Primary source paths
- SEC EDGAR company filings search
- Nasdaq market activity page
- brief.finance methodology and source checks
More Healthcare research hubs
- ABBV — AbbVie Inc.
- ABT — Abbott Laboratories
- AMGN — Amgen Inc.
- BMY — Bristol-Myers Squibb Company
- CI — The Cigna Group
- CVS — CVS Health Corporation
- DHR — Danaher Corporation
- ELV — Elevance Health, Inc.
- Browse all Healthcare research hubs
Author and editorial responsibility
By Joseph, Founder and editor, brief.finance. Every brief is generated under a fixed editorial and compliance method operated by Reaktif LLC.
About the author · Disclosures · Stock Directory
Ticker catalog last updated 2026-10-19.